Can Depakote (valproate) cause suicidal ideation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 14, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Depakote Can Cause Suicidal Ideation

Yes, Depakote (valproate) can cause suicidal ideation, as it carries an FDA black box warning for increased risk of suicidal thoughts and behavior like all antiepileptic drugs. 1 The risk is approximately twice that of placebo in clinical trials, with an estimated incidence rate of 0.43% in antiepileptic drug-treated patients compared to 0.24% in placebo-treated patients.

FDA Warning and Risk Assessment

Valproate, like all antiepileptic drugs (AEDs), carries the following risks:

  • Pooled analyses of 199 placebo-controlled clinical trials showed patients taking AEDs had approximately twice the risk of suicidal thinking or behavior compared to placebo (adjusted Relative Risk 1.8,95% CI: 1.2.7) 1
  • This represents approximately one additional case of suicidal thinking or behavior for every 530 patients treated 1
  • The increased risk was observed as early as one week after starting treatment and persisted throughout the treatment duration assessed 1
  • The risk applies across all AEDs regardless of their mechanism of action and across all indications 1

Risk Factors and Monitoring

Certain patient populations may be at higher risk for developing suicidal ideation when taking Depakote:

  • Patients with pre-existing psychiatric disorders
  • Patients with epilepsy (higher relative risk than psychiatric or other conditions, though absolute risk differences were similar) 1
  • Children and adolescents (FDA warning specifically addresses this population) 2, 3

Healthcare providers should:

  • Monitor all patients taking Depakote for the emergence or worsening of depression, suicidal thoughts or behavior, and unusual changes in mood or behavior 1
  • Be particularly vigilant during the first few months of treatment and after dose changes 1
  • Educate patients, caregivers, and families about the risk and advise them to be alert for concerning symptoms 1

Comparative Risk Among Antiepileptic Drugs

While the FDA warning applies to all antiepileptic drugs as a class, there are some differences in the literature regarding specific medications:

  • A 2007 review suggested that valproate might have some protective effects against suicidality due to its serotonergic properties, unlike phenobarbital and phenytoin which were associated with higher suicide risk 4
  • However, a 2019 systematic review and meta-analysis found no significant difference in the incidence rates of suicide attempts (RR 0.921; 95% CI 0.383-2.215) or completed suicides (RR 0.607; 95% CI 0.180-2.043) between bipolar patients receiving divalproex versus no medication 5

Clinical Implications

When prescribing Depakote:

  1. Perform a thorough suicide risk assessment before initiating treatment
  2. Discuss the risk of suicidal ideation with patients and caregivers
  3. Schedule more frequent follow-up visits during the initial treatment period and after dose adjustments
  4. Instruct patients and caregivers to report any emergence of suicidal thoughts, depression, or unusual changes in behavior immediately
  5. Consider the risk-benefit ratio, especially in patients with a history of suicidal ideation or attempts

Conclusion

While Depakote is an effective medication for several conditions including epilepsy and bipolar disorder, clinicians must balance its therapeutic benefits against the risk of suicidal ideation. The FDA black box warning applies to all antiepileptic drugs including Depakote, requiring careful monitoring throughout treatment.

Related Questions

What are the guidelines for using Depakote (Valproate) in skilled nursing facilities (SNFs), including indications, dosing, therapeutic levels, monitoring, and potential risks?
What is the best treatment approach for an elderly patient with depression and suicidal ideation who has not responded to sertraline (Zoloft) and escitalopram (Lexapro), experienced adverse effects with brexpiprazole (Rexulti), and is being weaned off lorazepam (Ativan) due to dependence concerns?
Are there any interactions between Epilim (valproate) and escitalopram?
Is there a liquid formulation of divalproex (valproate) sodium available?
In a 16‑year‑old female with major depressive disorder on fluoxetine (Prozac) for five months who remains depressed and reports suicidal ideation when a relative urges her to attend school, what additional treatment options should be considered?
Do you treat a pregnant female with a bacterial load of less than 10,000 colony forming units (CFU), who is asymptomatic?
Can you take Seroquel (quetiapine) and Caplyta (lumateperone) together?
What is the next step in managing a 93-year-old female patient with hypertension who is currently taking amlodipine 10mg daily and metoprolol 25mg PO bid?
What is the recommended antidote for morphine (opioid) overdose in a patient with Chronic Kidney Disease (CKD)?
Is testosterone therapy appropriate for patients with impaired renal function (low Glomerular Filtration Rate (GFR)) and elevated creatinine levels?
What is the recommended procedure for discontinuing Auvelity (dextromethorphan/bupropion)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.